Search Results - "ZAIN, Jasmine M"

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study by O'CONNOR, Owen A, PRO, Barbara, JACOBSEN, Eric, LUIGI ZINZANI, Pier, FURMAN, Richard, GOY, Andre, HAIOUN, Corinne, CRUMP, Michael, ZAIN, Jasmine M, HSI, Eric, BOYD, Adam, HORWITZ, Steven, PINTER-BROWN, Lauren, BARTLETT, Nancy, POPPLEWELL, Leslie, COIFFIER, Bertrand, JO LECHOWICZ, Mary, SAVAGE, Kerry J, SHUSTOV, Andrei R, GISSELBRECHT, Christian

“…Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's lymphoma with no accepted standard of care. This study evaluated the efficacy…”
Get full text

Aggressive T‐cell lymphomas: 2019 updates on diagnosis, risk stratification, and management by Zain, Jasmine M.

“…Introduction Aggressive T‐cell lymphomas continue to have a poor prognosis. There are over 27 different subtypes of peripheral T‐cell lymphoma (PTCL) and we…”
Get full text

Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation by Armenian, Saro H., Iukuridze, Aleksi, Teh, Jennifer Berano, Mascarenhas, Kristen, Herrera, Alex, McCune, Jeannine S., Zain, Jasmine M., Mostoufi‐Moab, Sogol, McCormack, Shana, Slavin, Thomas P., Scott, Jessica M., Jones, Lee W., Sun, Can‐Lan, Forman, Stephen J., Wong, F. Lennie, Nakamura, Ryotaro

“…Background The number of patients undergoing autologous haematopoietic cell transplant (HCT) is growing, but little is known about the factors that predict…”
Get full text

Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management by Zain, Jasmine M., Hanona, Paul

“…Introduction Aggressive T‐cell lymphomas continue to have a poor prognosis. There are over 27 different subtypes of peripheral T‐cell lymphoma (PTCL), and we…”
Get full text

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management by Ong, Shin Yeu, Zain, Jasmine M.

“…Introduction Aggressive T‐cell lymphomas continue to have a poor prognosis. There are over 30 different subtypes of peripheral T‐cell lymphoma (PTCL), and we…”
Get full text

Targeted treatment and new agents in peripheral T-cell lymphoma by Zain, Jasmine M., O’Connor, Owen

“…Mature T-cell and NK-cell lymphomas are increasingly being recognized as unique biological entities distinguishable from other forms of lymphomas. Treatment…”
Get full text

Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience by Folkes, Alecia S, Feng, Mingye, Zain, Jasmine M, Abdulla, Farah, Rosen, Steven T, Querfeld, Christiane

“…PURPOSE OF REVIEWTo describe the relevance of CD47 in the tumor microenvironment and summarize data on anti-CD47 therapies, including its role in cutaneous…”
Get full text

United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic by Zic, John A., Ai, Weiyun, Akilov, Oleg E., Carter, Joi B., Duvic, Madeleine, Foss, Francine, Girardi, Michael, Gru, Alejandro A., Kim, Ellen, Musiek, Amy, Olsen, Elise A., Schieke, Stefan M., Shinohara, Michi, Zain, Jasmine M., Geskin, Larisa J.

Get full text

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study by Hamadani, Mehdi, Collins, Graham P, Caimi, Paolo F, Samaniego, Felipe, Spira, Alexander, Davies, Andrew, Radford, John, Menne, Tobias, Karnad, Anand, Zain, Jasmine M, Fields, Paul, Havenith, Karin, Cruz, Hans G, He, Shui, Boni, Joseph, Feingold, Jay, Wuerthner, Jens, Horwitz, Steven

“…Novel approaches are required to improve outcomes in relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. We aimed to evaluate…”
Get full text

Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma by Chavez, Julio C, Foss, Francine M, William, Basem M, Brammer, Jonathan E, Smith, Sonali M, Prica, Anca, Zain, Jasmine M, Tuscano, Joseph M, Shah, Harsh, Mehta-Shah, Neha, Geethakumari, Praveen Ramakrishnan, Wang, Ben X, Zantinge, Stephanie, Wang, Lisa, Zhang, Ling, Boutrin, Anmarie, Zhao, Weiguang, Cheng, Lily, Standifer, Nathan, Hewitt, Lisa, Enowtambong, Enowmpey, Shao, Weiping, Sharma, Shringi, Carlesso, Gianluca, Moscow, Jeffrey A, Siu, Lillian L

“…Proliferation of T-follicular helper (TFH) CD4+ T cells is a postulated pathogenic mechanism for T-cell non-Hodgkin lymphomas (T-NHL). The inducible T-cell…”
Get full text

Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T‐cell lymphoma by Stuver, Robert, Horwitz, Steven M., Advani, Ranjana H., Vose, Julie M., Lee, Hun Ju, Mehta‐Shah, Neha, Zain, Jasmine M., Haverkos, Bradley, Lechowicz, Mary Jo, Moskowitz, Alison J., Pham, Luu Q., Leyden, Elizabeth, Ansell, Stephen M., Lunning, Matthew A.

“…Summary There remains no one standard induction for nodal‐based peripheral T‐cell lymphoma (PTCL). We conducted a phase II study of lenalidomide plus CHOEP as…”
Get full text

Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors by Montanari, Francesca, MD, O'Connor, Owen A., MD, PhD, Savage, David G., MD, Zain, Jasmine M., MD, Venkatraman, Seshan, PhD, McCormick, Erin K., BS, Crook, Meaghan T., BS, Tsao, Lawrence, MD, Sevilla, Deborah W., MD, Bhagat, Govind, MD, Alobeid, Bachir, MD

“…Summary Posttransplant lymphoproliferative disorders are classified as monomorphic, polymorphic, early lesions, or Hodgkin lymphoma type. Staging bone marrow…”
Get full text

A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma by Merrill, Mwanasha H, Dahi, Parastoo B, Redd, Robert A, McDonough, Mikaela M, Chen, Yi-Bin, DeFilipp, Zachariah, Herrera, Alex F, Fisher, David C, LaCasce, Ann S, Odejide, Oreofe O, Ng, Samuel Y, Jacobson, Caron A, Merryman, Reid W, Kim, Austin I, Nieto, Yago L, Sauter, Craig S, Shah, Gunjan L, Zain, Jasmine M, Armand, Philippe, Jacobsen, Eric D

“…Autologous stem cell transplantation (ASCT) is often used as consolidation for several subtypes of peripheral T-cell lymphoma (PTCL) in first remission…”
Get full text

Letermovir and maribavir for pan‐resistant cytomegalovirus infection in a patient with haematologic malignancy: Consideration for combination therapy by Dickter, Jana K., Ross, Justine A., Zain, Jasmine M., Tegtmeier, Bernard R., Lee, Brian V., Dadwal, Sanjeet S.

“…What is known and objective Management of pan‐resistant cytomegalovirus infection (CMVi) requires a multifaceted approach, including host defence optimization…”
Get full text

Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study by Querfeld, Christiane, Thompson, John A, Taylor, Matthew H, DeSimone, Jennifer A, Zain, Jasmine M, Shustov, Andrei R, Johns, Carolyn, McCann, Sue, Lin, Gloria H Y, Petrova, Penka S, Uger, Robert A, Molloy, Naomi, Shou, Yaping, Akilov, Oleg E

“…Intravenous TTI-621 (SIRPα-IgG1 Fc) was previously shown to have activity in relapsed or refractory haematological malignancies. This phase 1 study evaluated…”
Get full text

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma by Horwitz, Steven M., Kim, Youn H., Foss, Francine, Zain, Jasmine M., Myskowski, Patricia L., Lechowicz, Mary Jo, Fisher, David C., Shustov, Andrei R., Bartlett, Nancy L., Delioukina, Maria L., Koutsoukos, Tony, Saunders, Michael E., O'Connor, Owen A., Duvic, Madeleine

“…Systemic treatment for cutaneous T-cell lymphoma (CTCL) involves the use of less aggressive, well-tolerated therapies. Pralatrexate is a novel antifolate with…”
Get full text

Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies by MARCHI, Enrica, PAOLUZZI, Luca, SCOTTO, Luigi, SESHAN, Venkatraman E, ZAIN, Jasmine M, LUIGI ZINZANI, Pier, O'CONNOR, Owen A

“…Pralatrexate (10-propargyl-10-deazaaminopterin) is an antifolate with improved cellular uptake and retention due to greater affinity for the reduced folate…”
Get full text

A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517 by Kirschbaum, Mark H., Goldman, Bryan H., Zain, Jasmine M., Cook, James R., Rimsza, Lisa M., Forman, Stephen J., Fisher, Richard I.

“…Abstract We performed a phase II study of oral vorinostat (200 mg twice daily, days 1-14 of a 21-day cycle), a histone and protein deacetylase inhibitor, to…”
Get full text

A Critical Analysis of Prognostic Factors in North American Patients With Human T- Cell Lymphotropic Virus Type-1-Associated Adult T-Cell Leukemia/Lymphoma: A Multicenter Clinicopathologic Experience and New Prognostic Score by PHILLIPS, Adrienne A, SHAPIRA, Iuliana, ALOBEID, Bachir, SESHAN, Venkatraman E, O'CONNOR, Owen A, WILLIM, Robert D, SANMUGARAJAH, Jasotha, SOLOMON, William B, HORWITZ, Steven M, SAVAGE, David G, BHAGAT, Govind, SOFF, Gerald, ZAIN, Jasmine M

“…To define the clinicopathologic and prognostic features of patients with human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell…”
Get full text

The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas by Bhansali, Rahul S., Ellin, Fredrik, Relander, Thomas, Cao, Miao, Li, Wenrui, Long, Qi, Ganesan, Nivetha, Stuver, Robert, Horwitz, Steven M., Wudhikarn, Kitsada, Hwang, Steven R., Bennani, N. Nora, Chavez, Julio, Sokol, Lubomir, Saeed, Hayder, Duan, Frank, Porcu, Pierluigi, Pullarkat, Priyanka, Mehta-Shah, Neha, Zain, Jasmine M., Ruiz, Miguel, Brammer, Jonathan E., Prakash, Rishab, Iyer, Swaminathan P., Olszewski, Adam J., Major, Ajay, Riedell, Peter A., Smith, Sonali M., Goldin, Caroline, Haverkos, Bradley, Hu, Bei, Zhuang, Tony Z., Allen, Pamela B., Toama, Wael, Janakiram, Murali, Brooks, Taylor R., Jagadeesh, Deepa, Hariharan, Nisha, Goodman, Aaron M., Hartman, Gabrielle, Ghione, Paola, Fayyaz, Fatima, Rhodes, Joanna M., Chong, Elise A., Gerson, James N., Landsburg, Daniel J., Nasta, Sunita D., Schuster, Stephen J., Svoboda, Jakub, Jerkeman, Mats, Barta, Stefan K.

“…•Tumor histology and number of sites of extranodal involvement are prominent risk factors for CNS relapse.•The CITI score is a validated risk model to predict…”
Get full text